Eisai plants molecular glue SEED with $1.5B biobucks deal in neuro, oncology

cafead

Administrator
Staff member
  • cafead   Aug 06, 2024 at 11:22: AM
via Big Pharmas remain stuck to the idea of molecular glue degraders. The latest company to see an opportunity is Japan’s Eisai, which has signed a $1.5 billion biobucks pact with SEED Therapeutics for undisclosed neurodegeneration and oncology targets.

article source